SS Innovations International (NASDAQ: SSII) announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year, driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system to 30 units. The company's gross profit climbed 20% to $7.1 million, maintaining a gross margin of 50.9%. Despite a net loss of $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million a year earlier, the company's strategic investments in global expansion and regulatory processes are beginning to bear fruit.
First-half revenue surged 65.6% to $25 million, with installations up 47.4% to 56 systems. As of June 30, SS Innovations had a cumulative installed base of 224 SSi Mantra systems across 12 countries, and had performed 12,272 procedures, including 175 telesurgeries. Notably, the company recently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's long-distance capabilities and potential for expanding access to surgical care in underserved regions.
The company's financial position remains solid, with $13.6 million in cash and cash equivalents and no long-term debt as of June 30. This financial stability supports ongoing operations and regulatory pursuits. SS Innovations expects the U.S. Food and Drug Administration to complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027, and the company believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are critical for entering major markets and could significantly expand the company's addressable market.
According to the press release, the company's vision is to make robotic surgery affordable and accessible globally. With a focus on cost-effective solutions, SS Innovations aims to differentiate itself in a market dominated by more expensive systems. The SSi Mantra's telesurgery capabilities could be a game-changer, enabling remote surgeries across vast distances, which is particularly relevant for addressing surgical shortages in developing countries.
The record revenue and installation growth underscore strong demand for the SSi Mantra, but the company's path to profitability remains a challenge. The increased net loss in Q2, despite higher revenue, indicates heavy investment in R&D, regulatory processes, and global expansion. Investors will be watching for progress on FDA and CE approvals, as these will likely be key catalysts for future revenue growth.
SS Innovations' performance in the first half of 2026 sets a positive trajectory. The company's ability to nearly double installations year-over-year and achieve significant revenue growth highlights its market traction. With regulatory decisions pending, the next few quarters will be pivotal in determining whether SS Innovations can convert its operational momentum into sustained financial success and broader market penetration.
